Washington Post Runs Story on Potential Risks of Bitter Orange
On Tuesday, August 31 ABC Founder and Executive Director Mark Blumenthal was
interviewed by Lisa Barrett-Mann, a freelance writer for the Health section of
the Washington Post. She was writing an article about the paper
by Adriane Fugh-Berman, MD and Adam Myers of Georgetown University in which the
authors speculated on the potential adverse effects associated with bitter orange
extract (Citrus aurantium). Bitter orange is an increasingly popular
ingredient in dietary supplements for weight loss, especially since the FDA banned
ephedra (Ephedra sinica) earlier this year.
The Fugh-Berman and Myers paper, “Citrus aurantium, an Ingredient of Dietary
Supplements Marketed for Weight Loss: Current Status of Clinical and Basic Research”
was just published in Experimental Biology and Medicine (vol. 229). In
it the authors review literature on bitter orange and its primary alkaloid synephrine.
After reviewing studies on humans and animals, the authors suggest that until
short- and long-term safety studies are published on bitter
orange extract, consumers should avoid dietary supplements containing the ingredient.
The authors also noted that they were not aware of any adverse event reports associated
with bitter orange-containing supplements.
When asked to comment on the paper, Blumenthal noted that he knows Dr. Fugh-Berman
quite well and that she is a valued member of the ABC Advisory Board. He stated
that the paper demonstrated a hypertensive effect of synephrine and bitter orange
formulations when administered by injection or when a synthetic form of synephrine
was used, but that the authors acknowledged that oral administration of bitter
orange (the authors often refer to it by its synonym Seville orange) may have
a hemodynamic effect different from synephrine. The bottom line, said Blumenthal,
is the distinction between injection versus ingestion. Injected synephrine and
bitter orange showed a raise in BP, not so with oral use.
Blumenthal also stated that
there are no authoritative published reviews available on C. aurantium, so papers like this one that attempt to summarize
much of the safety data, drug interactions, and evidence (or lack thereof) for
clinical efficacy are welcome additions to the scientific and medical
literature. But, he cautioned, that based on this paper’s data and conclusions,
warnings about bitter orange safety are speculative and not based on solid
scientific or medical data.
The Washington Post article appeared on Tuesday, September 7.